Table A1.
Included FDA-Approved Drugs for the First-Line Treatment of Breast, Colon, and Lung Cancer With Number of Suppliers Over Time
| No. of Suppliers by Drug and Year | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | |
| Breast cancer drugs | ||||||||||||
| Anastrozole | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 16 | 19 | 19 | 19 |
| Cyclophosphamide | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Docetaxel | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 7 | 8 | ||
| Doxorubicin hydrochloride | 2 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 6 |
| Epirubicin hydrochloride | 1 | 1 | 1 | 1 | 2 | 7 | 7 | 7 | 8 | 7 | 7 | 8 |
| Exemestane | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | |||
| Fluorouracil | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| Lapatinib | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| Letrozole | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 10 | 10 | ||
| Methotrexate sodium | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 6 | 6 |
| Paclitaxel | 5 | 5 | 5 | 4 | 4 | 6 | 7 | 6 | 5 | 6 | 7 | 7 |
| Paclitaxel protein-bound | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Pertuzumab | 1 | 1 | ||||||||||
| Tamoxifen | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 |
| Trastuzumab | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||
| Colon cancer drugs | ||||||||||||
| Bevacizumab | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Capecitabine | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||
| Cetuximab | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Fluorouracil | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 |
| Irinotecan | 1 | 1 | 1 | 1 | 1 | 2 | 9 | 8 | 9 | 8 | 10 | 10 |
| Leucovorin calcium | 3 | 4 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| Oxaliplatin | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 5 | 7 | 7 | ||
| Panitumumab | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||
| Lung cancer drugs | ||||||||||||
| Afatinib dimaleate | 1 | |||||||||||
| Bevacizumab | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||
| Carboplatin | 1 | 1 | 5 | 8 | 9 | 8 | 9 | 7 | 6 | 5 | 4 | 5 |
| Cisplatin | 5 | 5 | 5 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 |
| Crizotinib | 1 | 1 | 1 | |||||||||
| Erlotinib hydrochloride | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Etoposide and etoposide phosphate | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 |
| Gefitinib | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||
| Gemcitabine | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 11 | 11 | 12 |
| Methotrexate sodium | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 6 | 6 |
| Paclitaxel | 5 | 5 | 5 | 4 | 4 | 6 | 7 | 6 | 5 | 6 | 7 | 7 |
| Pemetrexed disodium | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
NOTE. Information about the number of suppliers was obtained from the 2003-2009 Red Book: Pharmacy’s Fundamental Resource and the RED BOOK Online Database for subsequent years.
Abbreviation: FDA, US Food and Drug Administration.